Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINOCA secondary prevention trial of beta-blocker and ACEI/ARB
ACTRN12618001858280Phase 4Terminated
- Sponsor
- University of Adelaide
- Start
- Jan 2019
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of atenolol, perindopril and candesartan in myocardial infarction with nonobstructive coronary arteries (MINOCA), sponsored by University of Adelaide. Primary endpoint: Primary composite time-to-event endpoint. Started Jan 2019; status: terminated.
02
Drugs
atenololperindoprilcandesartan
03
Conditions
myocardial infarction with nonobstructive coronary arteries (MINOCA)
Beyond the preview
Go deeper on ACTRN12618001858280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001858280.